<DOC>
	<DOCNO>NCT00742222</DOCNO>
	<brief_summary>PRINCIPAL INVESTIGATORS - Rakesh Patel , MD- Radiation Oncologist - Peter Beitsch , MD- Breast Surgeon REGISTRY DESIGN - Multicenter , non-randomized , post market registry intracavitary accelerate partial breast irradiation appropriately select patient . SAMPLE SIZE AND SITES : - Approximately 400 patient may enrol . - Up 100 qualified U.S. site may participate registry . ENDPOINTS : 1 . PRIMARY ENDPOINTS - Subcutaneous Toxicities - The incidence sign symptoms subcutaneous toxicity record follow follow-up visit ; six ( 6 ) month , one ( 1 ) year , two ( 2 ) year , three ( 3 ) year , four ( 4 ) year , five ( 5 ) year . - Skin Toxicities - Specific toxicity result radiation therapy record follow-up visit . The Common Terminology Criteria Adverse Events use record follow-up visit ; one ( 1 ) month , six ( 6 ) month , one ( 1 ) year , two ( 2 ) year , three ( 3 ) year , four ( 4 ) year , five ( 5 ) year . - Cosmetic Outcome - Cosmetic outcome record follow follow-up visit ; one ( 1 ) month , six ( 6 ) month , one ( 1 ) year , two ( 2 ) year , three ( 3 ) year , four ( 4 ) year , five ( 5 ) year . Cosmetic outcome assess grade two way : - Patient Quality Life Questionnaire - A Quality Life Questionnaire ( QOL ) complete follow visit ; one ( 1 ) month , six ( 6 ) month , one ( 1 ) year , two ( 2 ) year , three ( 3 ) year , four ( 4 ) year , five ( 5 ) year . 2 . SECONDARY ENDPOINTS - Local-regional Breast Failure - The secondary efficacy endpoint ipsilateral breast failure five ( 5 ) year . This include : - Ipsilateral recurrence within initially treated volume . ( Within tumor bed ) - Ipsilateral recurrence cancer outside initially treated volume . ( Elsewhere Failure ) - Axillary nodal recurrence - Survival - record follow-up visit - Overall Survival - Disease Free Survival - Device Performance - record balloon applicator placement course radiation treatment : - Ability deliver treatment - Axxent System / Balloon Applicator performance 3 . TREATMENT DEVICE The device use electronic brachytherapy system treatment early stage breast cancer intracavitary accelerate partial breast irradiation . The device manufacturer Xoft , Incorporated . All Xoft technology clear FDA treatment early stage breast cancer use post market data collection registry . OVERSIGHT COMMITTEE Representatives American Brachytherapy Society ( ABS ) , American Society Breast Surgeons ( ASBS ) , American College Radiation Oncology ( ACRO ) oversee study management .</brief_summary>
	<brief_title>Electronic Xoft Intersociety Brachytherapy Trial : Electronic Brachytherapy ( EBT ) For Treatment Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<criteria>Patient 50 year age old Estrogen receptor positive Tumor size â‰¤ 3cm Tumor histology : invasive carcinoma DCIS Patient node negative Patient negative surgical margin ( NSABP definition , tumor ink ) final surgery Life expectancy &gt; 5 year Pregnancy breastfeeding . ( If appropriate , patient must use birth control registry . ) The need pregnancy test base physician 's standard practice perform accord physician 's standard care . Collagen Vascular Disease Scleroderma Systemic sclerosis Active lupus Infiltrating lobular histology Previous ipsilateral radiation thorax breast</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Electronic brachytherapy registry</keyword>
	<keyword>Multi-society registry</keyword>
	<keyword>Breast cancer registry</keyword>
</DOC>